Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24031578 | 0.89 | GAA (0.34) | GAASMN1; SMN2 | |
| SCHEMBL24031584 | 0.85 | GAA (0.34) | GAASMN1; SMN2 | |
| SCHEMBL24031598 | 0.83 | — | — | |
| SCHEMBL24035522 | 0.80 | GAA (0.31) | GAASMN1; SMN2 | |
| SCHEMBL20562547 | 0.73 | TGFBR1 (0.30) | — | |
| SCHEMBL30161393 | 0.69 | — | — | |
| SCHEMBL27032677 | 0.67 | TGFBR1 (0.33) | — | |
| SCHEMBL24035530 | 0.67 | GAA (0.32) | GAASMN1; SMN2 | |
| SCHEMBL168924 | 0.66 | GAA (0.30) | GAASMN1; SMN2 | |
| SCHEMBL24035535 | 0.64 | POLB (0.34) | GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219961-A1 | Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof | Suzhou Alphama Biotechnology Co., Ltd. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230219961-A1 | Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof | Suzhou Alphama Biotechnology Co., Ltd. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230192703-A1 | Polycyclic amide derivative as CDK9 inhibitor, preparation method therefor and use thereof | Suzhou Alphama Biotechnology Co., Ltd. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192703-A1 | Polycyclic amide derivative as CDK9 inhibitor, preparation method therefor and use thereof | Suzhou Alphama Biotechnology Co., Ltd. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192703-A1 | Polycyclic amide derivative as CDK9 inhibitor, preparation method therefor and use thereof | Suzhou Alphama Biotechnology Co., Ltd. (CN) | 2023-06-22 | — | — | US | disclosed |
| EP-4141004-A1 | POLYCYCLIC AMIDE DERIVATIVE AS CDK9 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Suzhou Alphama Biotechnology Co., Ltd. (CN) | 2023-03-01 | — | — | EP | disclosed |
| CN-113149996-B | Polycyclic amide derivative as CDK9 inhibitor, and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2022-12-20 | — | — | CN | disclosed |
| CN-115340555-A | Pyridine acetamide derivative as CDK inhibitor, and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2022-11-15 | — | — | CN | disclosed |
| CN-113173924-B | Pyridine acetamide derivative as CDK inhibitor, and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2022-07-19 | — | — | CN | disclosed |
| WO-2021227904-A1 | POLYCYCLIC AMIDE DERIVATIVE AS CDK9 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州阿尔脉生物科技有限公司 | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192703-A1 | Polycyclic amide derivative as CDK9 inhibitor, preparation method therefor and use thereof | CDK9, CDK8, CDK19 | GAA 4269/4885SMN1; SMN2 4642/4885 |
| US-20230219961-A1 | Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof | CDK9, CDK7, CDK8 | GAA 3655/4885SMN1; SMN2 4589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.